<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599882</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-LSM-CAP</org_study_id>
    <nct_id>NCT03599882</nct_id>
  </id_info>
  <brief_title>Liver Steatosis and Stiffness in HIV</brief_title>
  <official_title>Non-invasive Assessment of Liver Steatosis and Stiffness in HIV-infected Patients With Controlled Attenuation Parameter and Transient Elastography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      With the advances in treatment and clinical care, individuals with human immunodeficiency
      virus (HIV) infection have experienced an increase in life expectancy. Liver disease is
      common among HIV-infected patients due to the shared routes of transmission of HIV and viral
      hepatitis. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated
      aminotransferases in HIV-monoinfected adults without HBV or HCV.

      Vibration-controlled transient elastography (VCTE) has been shown to have good sensitivity
      and specificity for assessment of liver fibrosis in HIV and viral hepatitis coinfected
      patients, as well as in HIV-negative NASH population. Controlled attenuation parameter (CAP),
      a novel physical parameter developed using the postulate that fat affects ultrasound
      propagation, measures the ultrasound attenuation at the center frequency of the FibroScanÂ®.

      Study design:

      This is a prospective observational study.

      Objective:

      The aim of this study is to evaluate the liver steatosis and fibrosis in HIV-infected
      patients by noninvasive methods of VCTE and CAP.

      Methods:

      Patient number: 200

      Inclusion criteria:

        1. Age: 20-65 years

        2. Males and females with HIV infection diagnosed by infection doctors

        3. Willing and able to comply with the study requirements

        4. Willing and able to provide written informed consent to participate in the study

      Exclusion criteria:

        1. Pregnancy

        2. Unable to complete the noninvasive procedure of VCTE and CAP

        3. Unwilling to provide written informed consent to participate in the study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The changes of liver steatosis in HIV-infected patients by FibroScan (CAP)</measure>
    <time_frame>2 years</time_frame>
    <description>The liver steatosis will be evaluated by controlled attenuation parameter at 6-month interval. The overtime changes will be explored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The changes of liver fibrosis in HIV-infected patients by Fibroscan (VCTE)</measure>
    <time_frame>2 years</time_frame>
    <description>The liver fibrosis will be assessed by transient elastography at 6-month interval. The overtime changes will be explored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The association between FIB-4 and liver fibrosis</measure>
    <time_frame>2 years</time_frame>
    <description>FIB-4 will be calculated by a formula. FIB-4=[age(year)*AST(U/L)]/[platelet count*ALT(U/L)^0.5]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between BMI and liver steatosis</measure>
    <time_frame>2 years</time_frame>
    <description>BMI is combination of BW and BH and presented as kg/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between lipid profile and liver steatosis</measure>
    <time_frame>2 years</time_frame>
    <description>Lipid profile includes cholesterol, triglyceride, HDL cholesterol, LDL cholesterol.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV Infections</condition>
  <condition>Fatty Liver</condition>
  <condition>Liver Fibroses</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fibroscan</intervention_name>
    <description>Fibroscan with controlled attenuation parameter and transient elastography</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HIV infection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 20-65 years

          2. Males and females with HIV infection diagnosed by infection doctors

          3. Willing and able to comply with the study requirements

          4. Willing and able to provide written informed consent to participate in the study

        Exclusion Criteria:

          1. Pregnancy

          2. Unable to complete the noninvasive procedure of VCTE and CAP

          3. Unwilling to provide written informed consent to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Cheng Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Cheng Chen, MD</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>8107</phone_ext>
    <email>yichengliver@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Cheng Chen, MD</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>8107</phone_ext>
      <email>yichengliver@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chun-Wen Cheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fang-Hsueh Yuan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Cheng Chen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>human immunodeficiency virus</keyword>
  <keyword>liver steatosis</keyword>
  <keyword>liver fibrosis</keyword>
  <keyword>controlled attenuation parameter</keyword>
  <keyword>transient elastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

